JPRN-UMIN000024227已完成未知
Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infection - Daclatasvir and Asunaprevir therapy for hemodialyzed ptatients
others0 个研究点目标入组 130 人开始时间: 2016年9月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1patients with heart failure 2patients with decompensated cirrhosis 3patients with allergic to NS5A inhibitor or HCV PI inhibitor 4 patients with HCC or other malignant disease
研究者
相似试验
已完成
不适用
Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with chronic hepatitis Chemodialyzed patients with chronic hepatitis CJPRN-UMIN000016355Hokkaido University Hospital100
已完成
不适用
Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysisChronic hepatitis C with hemodialysisJPRN-UMIN000016181shonan kamakura general hospital30
已完成
不适用
Efficacy and safety of daclatasvir and asunaprevir in patients with chronic hepatitis CPatients with chronic hepatitis C virus infectionJPRN-UMIN000015247Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology350
Unknown
4 期
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis CHepatitis C, ChronicNCT02639585Pusan National University Hospital32
已完成
3 期
A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects with Chronic Hepatitis C Genotype 1b Infection.;+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 13-Mar-12)Chronic Hepatitis C infection or Chronic HCV10047438Hepatitis CNL-OMON37621Bristol-Myers Squibb18